Beta Blockers Global Market Report 2025

Beta blockers, also recognized as beta-adrenergic blocking agents, constitute a medication class widely employed in managing diverse cardiovascular conditions by mitigating heart activity. Their common prescription aims at regulating blood pressure, addressing angina, managing heart failure, and addressing certain cardiac rhythm irregularities.

Within the beta blockers spectrum, two primary types include non-selective agents and selective agents. Non-selective agents within the beta-blockers market encompass medications that impede or obstruct beta-adrenergic receptors' effects without a specific affinity toward any particular subtype. These agents serve to regulate various physiological functions encompassing heart rate, blood pressure, bronchial smooth muscle tone, and peripheral vascular resistance. Their use spans across conditions such as angina pectoris, heart failure, high blood pressure, and other ailments, often managed through medications such as betaxolol, acebutolol, esmolol, among others. These drugs are available through hospital pharmacies, retail outlets, and online platforms, catering to the treatment of cardiac diseases, hypertension, glaucoma, and related conditions.

The beta blockers market research report is one of a series of new reports from The Business Research Company that provides beta blockers market statistics, including beta blockers industry global market size, regional shares, competitors with a beta blockers market share, detailed beta blockers market segments, market trends, and opportunities, and any further data you may need to thrive in the beta blockers industry. This beta blockers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The beta blockers market size has grown strongly in recent years. It will grow from$9.67 billion in 2024 to $10.28 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to hypertension management, treatment of cardiovascular diseases, post-myocardial infarction care, migraine prophylaxis, and management of anxiety and tremors

The beta blockers market size is expected to see strong growth in the next few years. It will grow to $13.11 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to the prevalence of cardiovascular diseases, expanded applications in heart failure, combination therapies, focus on hypertension guidelines and exploration of novel indications. Major trends in the forecast period include application in anxiety and performance situations, potential neuroprotective effects, individualized treatment approaches, impact of generic versions, and integration with digital health platforms.

The increasing prevalence of cardiovascular diseases is projected to drive the growth of the beta blockers market. Cardiovascular diseases (CVDs) encompass a range of disorders that impact the heart and blood vessels. This rise in CVD incidence is primarily attributed to unhealthy diets, sedentary lifestyles, lack of physical activity, tobacco use, and obesity. Beta blockers can play a significant role in reducing cardiovascular cases by providing various beneficial effects on heart function and blood circulation. Consequently, the growing number of cardiovascular disease cases is fueling the expansion of the beta blockers market. For example, in September 2024, data from the British Heart Foundation, a UK-based cardiovascular research charity, revealed that around 7.6 million people in the UK are affected by heart and circulatory diseases. This includes approximately 4 million males and 3.6 million females. These diseases account for about 27% of all deaths in the UK, leading to over 170,000 fatalities each year, or roughly 480 deaths daily, which translates to one death every three minutes. Therefore, the rising incidence of cardiovascular diseases will contribute to the growth of the beta blockers market.

The mounting prevalence of glaucoma is poised to drive the beta blockers market's expansion. Glaucoma comprises a group of eye conditions leading to vision impairment and potential blindness by harming the optic nerve responsible for transmitting visual information to the brain. Beta blockers play a pivotal role in managing glaucoma by reducing intraocular pressure (IOP). Their mechanism involves diminishing the production of aqueous humor, the eye's internal fluid, thereby alleviating the pressure within the eye. For instance, as reported by the BrightFocus Foundation in October 2022, over three million Americans are affected by glaucoma, with 2.7 million individuals aged 40 and older experiencing its most prevalent form, open-angle glaucoma. Globally, 80 million people are afflicted by glaucoma, a figure anticipated to surpass 111 million by 2040.

Key players in the beta-blockers market are concentrating on developing innovative products, such as cardioselective beta-blockers and ultra-short-acting beta-blockers, to enhance patient outcomes related to cardiovascular health. Cardioselective beta-blockers specifically target B1 receptors in the heart, which helps reduce respiratory side effects and improves efficacy through advanced formulations. Ultra-short-acting beta-blockers, such as Landiolol, offer a rapid onset and offset of action, making them particularly suitable for acute care environments and critically ill patients who require swift heart rate management. For example, in January 2022, Eagle Pharmaceuticals, Inc., a pharmaceutical company based in the U.S., announced the submission of a new drug application (NDA) for Landiolol, a beta-1 adrenergic blocker intended for the short-term reduction of ventricular rates in patients experiencing supraventricular tachycardia, including atrial fibrillation and atrial flutter. This initiative aims to introduce Landiolol to the U.S. market, thereby expanding Eagle Pharmaceuticals' footprint in acute care and ultimately enhancing treatment options for patients with tachycardia.

Leading companies in the beta blockers sector are prioritizing the introduction of advanced beta blocking agents for severe hypertension management and blood pressure reduction, aiming to gain a competitive advantage. Beta blockers play a crucial role in addressing severe hypertension and lowering blood pressure by blocking peripheral arteriolar alpha-adrenoceptors, thus reducing peripheral resistance and safeguarding the heart from reflex sympathetic drive. For instance, in March 2023, Hikma Pharmaceuticals PLC launched Labetalol Hydrochloride (Labetalol HCl) Injection, USP, in prefilled syringe (PFS) form in the US for treating severe hypertension and reducing blood pressure. Labetalol combines selective alpha1-adrenergic blocking and nonselective beta-adrenergic blocking activities in a single substance, functioning primarily by blocking peripheral arteriolar alpha-adrenoceptors to decrease resistance and lower blood pressure.

In April 2023, Marksans Pharma, a pharmaceutical company based in India, acquired a manufacturing facility from Teva Pharmaceutical Industries for an undisclosed sum. This acquisition is intended to double Marksans Pharma's production capacity in India, solidifying its position as a prominent low-cost manufacturer and enabling it to effectively meet the increasing demands of its customer base. Teva Pharmaceutical Industries Ltd., based in Israel, is a multinational pharmaceutical company involved in the development, manufacturing, and commercialization of generic and specialty medications.

Major companies operating in the beta blockers market include Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca plc, Johnson and Johnson, Eli Lilly and Company, Sanofi SA, Bristol-Myers Squibb Company, Bayer AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Abbott Laboratories, Eagle Pharmaceuticals Inc., Neon Healthcare Ltd., Midas Pharma GmbH, Global Calcium PVT. LTD., AbbVie Inc., Mylan N.V., Boehringer Ingelheim International GmbH, Aspen Pharmacare Holdings Limited, Lupin Limited, Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Sandoz International GmbH, Wockhardt Ltd., Endo Pharmaceuticals Inc., Apotex Inc.

North America was the largest region in the beta blockers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global beta-blockers market report during the forecast period. The regions covered in the beta blockers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the beta blockers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The beta blockers market consists of sales of sales of metoprolol, nebivolol, timolol, and labetalol. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Beta Blockers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on beta blockers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for beta blockers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The beta blockers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Non-selective Agents; Selective Agents
• 2) By Indication: Angina Pectoris; Heart Failure; High Blood Pressure; Other Indications
• 3) By Drugs: Betaxolol; Acebutolol; Esmolol; Other Drugs
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• 5) By Application: Cardiac Diseases; Hypertension; Glaucoma; Other Applications
• Subsegments:
• 1) By Non-Selective Agents: Propranolol; Nadolol; Timolol
• 2) By Selective Agents: Atenolol; Metoprolol; Bisoprolol; Nebivolol
• Companies Mentioned: Pfizer Inc.; Novartis AG; Merck & Co. Inc.; AstraZeneca plc; Johnson and Johnson
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.